drugset
drugset / Trial / NCT05015192

Single Ascending Dose Study of NH102 in Healthy Subjects

NCT05015192 ↗

Phase 1 Completed 55 enrolled Jiangsu Nhwa Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of NH102 when administered as single oral dose at escalating dose levels in healthy participants.

Timeline

Start
2021-08-12
Primary completion
2022-01-11
Completion
2022-01-11

Drugs

EvaluationDrugModalityDoseRoute
Subject NH102 Unknown 3 mg Oral
Subject NH102 Unknown 9 mg Oral
Subject NH102 Unknown 20 mg Oral
Subject NH102 Unknown 40 mg Oral
Subject NH102 Unknown 60 mg Oral
Subject NH102 Unknown 80 mg Oral

Indications

depressive disorder